https://blackmarble.com.tw/wp-content/uploads/2017/01/Screen-Shot-2017-03-28-at-10.25.01.png
81
211
Jamie
https://blackmarble.com.tw/wp-content/uploads/2017/04/萬豐logo.png
Jamie2020-10-12 01:01:042020-10-12 01:31:47生華科膽管癌新藥Silmitasertib臨床期中分析達標 將加速爭取藥證
https://blackmarble.com.tw/wp-content/uploads/2017/01/Screen-Shot-2017-03-28-at-10.25.01.png
81
211
Jamie
https://blackmarble.com.tw/wp-content/uploads/2017/04/萬豐logo.png
Jamie2020-08-29 01:28:272020-10-12 01:52:32生華科Silmitasertib今獲美國FDA緊急核准 台灣第一個新藥上新冠臨床
https://blackmarble.com.tw/wp-content/uploads/2017/01/Screen-Shot-2017-03-28-at-10.25.01.png
81
211
Jamie
https://blackmarble.com.tw/wp-content/uploads/2017/04/萬豐logo.png
Jamie2020-08-16 01:40:592020-10-12 01:51:57生華科CX-5461 獲劍橋大學點名 全球唯一靶向G-4 機制臨床藥物抑制乳癌
https://blackmarble.com.tw/wp-content/uploads/2019/10/CloudMile1-LOGO.jpg
227
452
Jamie
https://blackmarble.com.tw/wp-content/uploads/2017/04/萬豐logo.png
Jamie2019-11-13 10:39:172021-08-24 16:56:48AI雲端新創Cloudmile獲1.8億元Pre-B輪募資，將在台設立研發中心、翻倍員工數量
https://blackmarble.com.tw/wp-content/uploads/2017/03/巨-1.jpg
209
292
Jamie
https://blackmarble.com.tw/wp-content/uploads/2017/04/萬豐logo.png
Jamie2018-10-10 21:41:402018-10-10 21:56:22台北生技、藥物科技獎 新一代神農氏出列
https://blackmarble.com.tw/wp-content/uploads/2017/03/巨-1.jpg
209
292
Jamie
https://blackmarble.com.tw/wp-content/uploads/2017/04/萬豐logo.png
Jamie2018-10-10 21:20:102018-10-10 21:52:57巨生啟動二期臨床明年登興櫃
https://blackmarble.com.tw/wp-content/uploads/2017/03/巨-1.jpg
209
292
Jamie
https://blackmarble.com.tw/wp-content/uploads/2017/04/萬豐logo.png
Jamie2018-02-09 10:33:182018-03-07 10:36:38巨生生醫表現亮眼，顯影劑產品進程迅速已取得美FDA同意進入臨床二期試驗
https://blackmarble.com.tw/wp-content/uploads/2017/01/senwa.png
50
190
bouncin
https://blackmarble.com.tw/wp-content/uploads/2017/04/萬豐logo.png
bouncin2017-01-25 16:09:592017-04-06 10:02:55邁向掛牌之路 生華科獲櫃買中心通過上櫃案
https://blackmarble.com.tw/wp-content/uploads/2017/01/senwa.png
50
190
Jamie
https://blackmarble.com.tw/wp-content/uploads/2017/04/萬豐logo.png
Jamie2017-01-24 13:35:392017-03-28 10:34:06生華科上櫃案通過 新藥CX-5461獲國際期刊收錄近期將發表